[Hematological stability under ubenimex monotherapy in a patient with acute myelogenous leukemia developing marrow karyotypic changes during the course].

Abstract

We encountered a 71-year-old female with acute myelogenous leukemia (AML, M1), who maintained a steady hematological state for 22 months under ubenimex monotherapy. At the first medical examination in our hospital, the marrow cellularity was approximately 40% containing leukemic myeloblasts of 41.4% in the total nucleated cells, and the marrow cytogenetic study revealed 47, XX, + 8 in 13 of 20 cells analyzed. Nineteen months later, the bone marrow showed definite hypoplasia with leukemic blasts of 39.8% and chromosome finding of 46, XX, ins (10;?) (q11;?) in all cells analyzed. During the course, the patient has been doing well without transfusion of red blood cells or platelets.

• Authors: K Shimosegawa, Y Ono, T Sugawara, H Numaoka, H Oikawa, S Ito, T Utsugisawa, K Murai, Y Narigasawa, Y Miyairi
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 36 Issue 11 Pg. 1289-94 (Nov 1995) ISSN: 0485-1439 [Print] Japan
• PMID: 8691570 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• Leucine
• ubenimex

Topics

• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Bone Marrow Cells
• Chromosomes, Human, Pair 10
• Chromosomes, Human, Pair 8
• Female
• Humans
• Karyotyping
• Leucine (analogs & derivatives, therapeutic use)
• Leukemia, Myeloid, Acute (blood, drug therapy, genetics)
• Mutagenesis, Insertional
• Trisomy